- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Herantis Pharma Oyj (HRTIS)
Herantis Pharma Oyj stock price live, this page displays HE HRTIS stock exchange data. View the HRTIS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Herantis Pharma Oyj real time stock price chart below.
What Is the Herantis Pharma Oyj Stock Price Today?
The Herantis Pharma Oyj stock price today is 1.650.
What Is the Stock Symbol for Herantis Pharma Oyj?
The stock symbol for Herantis Pharma Oyj is "HRTIS."
What Stock Exchange Does Herantis Pharma Oyj Trade On?
Herantis Pharma Oyj is listed and trades on the Helsinki stock exchange.
Is Herantis Pharma Oyj a Good Stock to Buy?
Determining whether Herantis Pharma Oyj—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HRTIS quote. (ISIN: FI4000087861)
What Is the Herantis Pharma Oyj Stock Price Today?
The Herantis Pharma Oyj stock price today is 1.650.
What Is the Stock Symbol for Herantis Pharma Oyj?
The stock symbol for Herantis Pharma Oyj is "HRTIS."
What Stock Exchange Does Herantis Pharma Oyj Trade On?
Herantis Pharma Oyj is listed and trades on the Helsinki stock exchange.
Is Herantis Pharma Oyj a Good Stock to Buy?
Determining whether Herantis Pharma Oyj—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HRTIS quote. (ISIN: FI4000087861)
1.650
+0.030(+1.85%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.648
1.696
52 wk Range
1.440
3.870
HRTIS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6481.696
52 wk Range
1.4403.870
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HRTIS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
2.000
Upside
+21.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.000
(+21.21% Upside)
Herantis Pharma Oyj Earnings Call Summary for H1/2026
- Herantis ended H1 2026 with EUR 3.5M cash and EUR -0.7M equity; shares fell 4.5% to $1.614 amid financing concerns and negative equity position.
- Company faces EUR 22M-27M funding gap for phase II Parkinson's trial despite securing EUR 8M Horizon Europe grant; total need is EUR 30M-35M through readout.
- Lead asset HER-096 showed favorable safety and biological activity in phase I; phase II enrollment targeted for H1 2027 with interim data expected early 2029.
- Management pursuing pharma partnerships, equity financing, and non-dilutive funding; plans dual FDA and European CTA filing by end-2026 to attract partners.
- Phase II designed as decisive efficacy test for disease-modifying Parkinson's therapy; full data readout expected shortly after early 2029 interim results.
Last Updated: 2026/08/20, 10:12
Read Full TranscriptEarnings
Latest Release
Aug 20, 2026
EPS / Forecast
-0,06 / --
Revenue / Forecast
-- / --
Compare HRTIS to Peers and Sector
Metrics to compare | HRTIS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHRTISPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | 13.3x | −0.4x | |
PEG Ratio | 0.65 | 0.71 | 0.00 | |
Price/Book | −54.9x | 1.4x | 2.6x | |
Price / LTM Sales | - | 2.1x | 3.1x | |
Upside (Analyst Target) | 19.3% | 18.1% | 47.0% | |
Fair Value Upside | Unlock | −0.9% | 5.6% | Unlock |
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Herantis Pharma Oyj (HRTIS) Stock Price Today?
The Herantis Pharma Oyj stock price today is 1,650 EUR.
What Stock Exchange Does Herantis Pharma Oyj Trade On?
Herantis Pharma Oyj is listed and trades on the Helsinki Stock Exchange.
What Is the Stock Symbol for Herantis Pharma Oyj?
The stock symbol for Herantis Pharma Oyj is "HRTIS."
What Is the Herantis Pharma Oyj Market Cap?
As of today, Herantis Pharma Oyj market cap is 42,940M EUR.
What Is Herantis Pharma Oyj's Earnings Per Share (TTM)?
The Herantis Pharma Oyj EPS (TTM) is -0,272.
When Is the Next Herantis Pharma Oyj Earnings Date?
Herantis Pharma Oyj will release its next earnings report on Aug 20, 2026.
From a Technical Analysis Perspective, Is HRTIS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Herantis Pharma Oyj Stock Split?
Herantis Pharma Oyj has split 0 times.
How Many Employees Does Herantis Pharma Oyj Have?
Herantis Pharma Oyj has 14 employees.
What is the current trading status of Herantis Pharma Oyj (HRTIS)?
As of Aug 28, 2026, Herantis Pharma Oyj (HRTIS) is trading at a price of 1,650 EUR, with a previous close of 1,620 EUR. The stock has fluctuated within a day range of 1,648 EUR to 1,696 EUR, while its 52-week range spans from 1,440 EUR to 3,870 EUR.
What Is Herantis Pharma Oyj (HRTIS) Price Target According to Analysts?
The average 12-month price target for Herantis Pharma Oyj is 2,000 EUR, with a high estimate of 2 EUR and a low estimate of 2 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +21,21% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.